Asthma control and COPD symptom burden in patients using fixed-dose combination inhalers (SPRINT study)
Roche, Nicolas (Respiratory Medicine, Cochin Hospital, APHP Centre University of Paris, Institut Cochin (UMR1016), Paris, France)
Plaza, Vicente (Institut d'Investigació Biomèdica Sant Pau)
Backer, Vibeke (Copenhagen University. Department of Respiratory Medicine)
van der Palen, Job (Medical School Twente, Medisch Spectrum Twente (Països Baixos))
Cerveri, Isa (Unit of Respiratory Diseases, IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy)
Gonzalez, Chelo (Experior SL (La Pobla de Farnals, Comunitat valenciana))
Safioti, Guilherme (Teva Pharmaceutical Industries Ltd, Amsterdam, The Netherlands)
Scheepstra, Irma (Teva Pharmaceutical Industries Ltd, Amsterdam, The Netherlands)
Patino, Oliver (Teva Pharmaceutical Industries Ltd, Amsterdam, The Netherlands)
Singh, Dave (Centre for Respiratory Medicine and Allergy, University of Manchester, and the Medicines Evaluation Unit, University Hospital of South Manchester NHS Foundation Trust)
Universitat Autònoma de Barcelona

Data:	2020
Resum:	Previous studies have found suboptimal control of symptom burden to be widespread among patients with asthma and chronic obstructive pulmonary disease (COPD). The Phase IV SPRINT study was conducted in 10 countries in Europe to assess asthma disease control and COPD symptom burden in patients treated with a fixed-dose combination (FDC) of inhaled corticosteroids (ICS) and long-acting beta agonists (LABAs). SPRINT included 1101 patients with asthma and 560 with COPD; all were receiving treatment with an FDC of ICS/LABA, delivered via various inhalers. Data were obtained over a 3-month period, during a single routine physician's office visit. Asthma control was defined as Asthma Control Test (ACT) score >19. COPD symptom burden was assessed by COPD Assessment Test (CAT), with a CAT score <10 defining low COPD symptom burden. Among patients using any ICS/LABA FDC, 62% of patients with asthma had achieved disease control (ACT score >19) and 16% of patients with COPD had low symptom burden (CAT score <10).
Nota:	Altres ajuts: Medical writing support was provided by Ian Grieve of Ashfield Healthcare Communications, part of UDG Healthcare plc, and was funded by Teva Pharmaceuticals.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	Therapeutics ; Health care
Publicat a:	NPJ primary care respiratory medicine, Vol. 30 (january 2020) , ISSN 2055-1010

DOI: 10.1038/s41533-019-0159-1
PMID: 31911607

7 p, 593.4 KB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències de la salut i biociències > Institut de Recerca Sant Pau
Articles > Articles de recerca
Articles > Articles publicats